Antidepressant; Early antidepressant response; Second step antidepressant treatment; Switch within or across class; Switching strategy; Treatment-resistant depression; Medicine (all)
Abstract :
[en] “Switching” antidepressant consists in switching from an ineffective antidepressant to a new antidepressant from a similar or different mechanism of action. It is one of the most recommended second step options in treatment-resistant depression (TRD). The possibility of changing treatment following treatment failure is not limited to the issue of choosing which antidepressant will be prescribed in a further step. This strategy is much more complex and needs to consider a variety of factors relating to how to achieve this change in treatment. During a depressive episode that does not respond sufficiently to treatment, this phase is often painful for the patient and complicated for the clinician. On the one hand, it is necessary to make the difficult choice of another antidepressant, but also to reevaluate the clinical situation and to plan how to implement the change in the safest and most effective way. In this chapter, we address these issues from a clinical perspective, focusing on key elements of the switching strategy in TRD: implication in the definition of TRD, choice of second step treatment, and how to implement the treatment switch.
Disciplines :
Psychiatry
Author, co-author :
Souery, Daniel; PSYPLURIEL at EPSYLON - Psychiatric Care Network, Brussels, Belgium ; Laboratory of Psychological Medicine and Addictology, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
Pitchot, William ; Centre Hospitalier Universitaire de Liège - CHU > > Service de psychiatrie
Language :
English
Title :
Switching antidepressants in patients with treatment-resistant depression
Publication date :
2022
Main work title :
Managing Treatment-Resistant Depression: Road to Novel Therapeutics
Adli, M., Baethge, C., Heinz, A., Langlitz, N., & Bauer, M. (2005). Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. European Archives of Psychiatry and Clinical Neuroscience, 255(6), 387-400.
Al-Harbi, K. S. (2012). Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Preference and Adherence, 6, 369-388. doi:10.2147/PPA.S29716
Baldomero, E. B., Ubago, J. G., Cercós, C. L., Ruiloba, J. V., Calvo, C. G., & López, R. P. (2005). Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depression and Anxiety, 22(2), 68-76.
Bennabi, D., Yrondi, A., Charpeaud, T., Genty, J. B., Destouches, S., Lancrenon, S., Allaili, N., Bellivier, F., Bougerol, T., Camus, V., Doumy, O., Dorey, J. M., Haesebaert, F., Holtzmann, J., Lançon, C., Lefebvre, M., Moliere, F., Nieto, I., Rabu, C., … Courtet, P. (2019). Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation Fonda Mental). BMC Psychiatry, 19(1). doi:10.1186/s12888-019-2025-7
Bose, A., Tsai, J., & Li, D. (2012). Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clinical Drug Investigation, 32(6), 373-385. doi:10.2165/11631890-000000000-00000
Bschor, T. (2014). Lithium in the treatment of major depressive disorder. Drugs, 74(8), 855-862. doi:10.1007/s40265-014-0220-x
Bschor, T., & Baethge, C. (2010). No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy: Review. Acta Psychiatrica Scandinavica, 121(3), 174-179. doi:10.1111/j.1600-0447.2009.01458.x
Bschor, T., Bauer, M., & Adli, M. (2014). Chronische und therapieresistente Depression - Diagnostik und Stufentherapie. Deutsches Arzteblatt International, 111(45), 766-776. doi:10.3238/arztebl.2014.0766
Bschor, T., Kern, H., Henssler, J., Baethge, C., 2018. Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J. Clin. Psychiatry 79 (1). doi:10.4088/JCP.16r10749.
De Montigny, C., Silverstone, P. H., Debonnel, G., Blier, P., & Bakish, D. (1999). Venlafaxine in treatment-resistant major depression: A Canadian multicenter, open-label trial. Journal of Clinical Psychopharmacology, 19(5), 401-406. doi:10.1097/00004714-199910000-00003
Guideline on clinical investigation of medicinal products in the treatment of depression. (2013). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-depression_en.pdf
Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., Gao, K., Cui, X., & Nierenberg, A. A. (2010). Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: A double-blind, randomized pilot study in a chinese population. Journal of Clinical Psychopharmacology, 30(4), 357-364. doi:10.1097/JCP.0b013e3181e7784f
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., Niederehe, G., Ritz, L., & Trivedi, M. H. (2006). A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. American Journal of Psychiatry, 163(7), 1161-1172. doi:10.1176/ajp.2006.163.7.1161
Gauthier, C., Abdel-Ahad, P., & Gaillard, R. (2018). Recommandations pour switcher et arrêter les antidépresseurs. Encephale, 44(4), 379-386. doi:10.1016/j.encep.2018.08.001
Henssler, J., Bschor, T., & Baethge, C. (2016). Combining antidepressants in acute treatment of depression: A meta-analysis of 38 studies including 4511 patients. Canadian Journal of Psychiatry, 61(1), 29-43. doi:10.1177/0706743715620411
Huhn, M., Tardy, M., Spineli, L. M., Kissling, W., Förstl, H., Pitschel-Walz, G., Leucht, C., Samara, M., Dold, M., Davis, J. M., & Leucht, S. (2014). Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry, 71(6), 706-715. doi:10.1001/jamapsychiatry.2014.112
Ingelman-Sundberg, M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal, 5(1), 6-13. doi:10.1038/sj.tpj.6500285
Ionescu, D. F., Rosenbaum, J. F., & Alpert, J. E. (2015). Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues in Clinical Neuroscience, 17(2), 111-126.
Jefferson, JW. (2000). Strategies for switching antidepressants to achieve maximum efficacy adolescents. J Clin Psychiatry, 69(1), 124-135.
Kaplan, E. M. (2002). Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: An open-label, uncontrolled study. Clinical Therapeutics, 24(7), 1194-1200. doi:10.1016/S0149-2918(02)80029-7
Kasper, S., Montgomery, S., Souery, D., Pitchot, W., 2013. Definitions and predictors of treatment‐resistant depression. In: Kasper, S., Montgomery, S. (Eds.), Treatment‐resistant Depression. John Wiley & Sons, Hoboken, NJ.
Kasper, S., Cubała, W. J., Fagiolini, A., Ramos-Quiroga, J. A., Souery, D., & Young, A. H. (2020). Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance. The World Journal of Biological Psychiatry : The Official Journal of the World Federation of Societies of Biological Psychiatry, 1-15. doi:10.1080/15622975.2020.1836399
Keks, N., Hope, J., & Keogh, S. (2016). Switching and stopping antidepressants. Australian Prescriber, 39(3), 76-83. https://doi.org/10.18773/austprescr.2016.039
Kornstein, S. G., & Schneider, R. K. (2001). Clinical features of treatment-resistant depression. Journal of Clinical Psychiatry, 62(16), 18-35.
Kudlow, P. A., McIntyre, R. S., & Lam, R. W. (2014). Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs, 28(7), 601-609. doi:10.1007/s40263-014-0171-5
Lamy, F. X., Chollet, J., Clay, E., Brignone, M., Rive, B., & Saragoussi, D. (2015). Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis. Current Medical Research and Opinion, 31(4), 795-807. doi:10.1185/03007995.2015.1020362
McGrath, P. J., Stewart, J. W., Harrison, W., & Quitkin, F. M. (1987). Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacology Bulletin, 23(1), 169-172.
McIntyre, R.S., 2010. When should you move beyond first-line therapy for depression? J. Clin. Psychiatry 71 (Suppl. 1), 16-20. doi:10.4088/JCP.9104su1c.03.
Nebert, D. W., & Dieter, M. Z. (2000). The evolution of drug metabolism. Pharmacology, 61(3), 124-135.
Nelson, J. C., & Papakostas, G. I. (2009). Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. The American Journal of Psychiatry, 166(9), 980-991. doi:10.1176/appi.ajp.2009.09030312
Nierenberg, A. A., Feighner, J. P., Rudolph, R., Cole, J. O., & Sullivan, J. (1994). Venlafaxine for treatment-resistant unipolar depression. Journal of Clinical Psychopharmacology, 14(6), 419-423. doi:10.1097/00004714-199412000-00008
Olgiati, P., Serretti, A., Souery, D., Dold, M., Kasper, S., Montgomery, S., Zohar, J., & Mendlewicz, J. (2018). Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. Journal of Affective Disorders, 227, 777-786. doi:10.1016/j.jad.2017.11.004
Papakostas, G.I., Perlis, R.H., Scalia, M.J., Petersen, T.J., Fava, M., 2006. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J. Clin. Psychopharmacol. 26 (1), 56-60.
Papakostas, G.I., Fava, M., & Thase, M. E. (2008). Treatment of SSRI-Resistant Depression: A Meta-Analysis Comparing Within- Versus Across-Class Switches. Biological Psychiatry, 63(7), 699-704. doi:10.1016/j.biopsych.2007.08.010
Poirier, M. F., & Boyer, P. (1999). Venlafaxine and paroxetine in treatment-resistant depression. Double- blind, randomised comparison. British Journal of Psychiatry, 175, 12-16. doi:10.1192/bjp.175.1.12
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. American Journal of Psychiatry, 176(6), 428-438. doi:10.1176/appi.ajp.2019.19020172
Ruhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006a). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: A systematic review. Journal of Clinical Psychiatry, 67(12), 1836-1855. doi:10.4088/JCP.v67n1203
Rush, A.J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917. doi:10.1176/ajp.2006.163.11.1905
Rush, A John, Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. The New England Journal of Medicine, 354(12), 1231-1242.
Rush, A John, South, C., Jha, M. K., Jain, S. B., & Trivedi, M. H. (2020). What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. The Journal of Clinical Psychiatry, 81(5). doi:10.4088/JCP.19m12949
Souery, D., Amsterdam, J., De Montigny, C., Lecrubier, Y., Montgomery, S., Lipp, O., Racagni, G., Zohar, J., & Mendlewicz, J. (1999). Treatment resistant depression: Methodological overview and operational criteria. European Neuropsychopharmacology, 9(1-2), 83-91. doi:10.1016/S0924-977X(98)00004-2
Souery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., Zohar, J., & Mendlewicz, J. (2007). Clinical factors associated with treatment resistance in major depressive disorder: Results from a European multicenter study. Journal of Clinical Psychiatry, 68(7), 1062-1070. doi:10.4088/jcp.v68n0713
Souery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Zohar, J., & Mendlewicz, J. (2011). Switching antidepressant class does not improve response or remission in treatment-resistant depression. Journal of Clinical Psychopharmacology, 31(4), 512-516. doi:10.1097/JCP.0b013e3182228619
Souery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Kasper, S., Montgomery, S., Zohar, J., & Mendlewicz, J. (2011). Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. The World Journal of Biological Psychiatry : The Official Journal of the World Federation of Societies of Biological Psychiatry, 12(5), 364-375. doi:10.3109/15622975.2011.590225
Thase, M. E., Frank, E., Mallinger, A. G., Hamer, T., & Kupfer, D. J. (1992). Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. Journal of Clinical Psychiatry, 53(1), 5-11.
Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. (2003). Lancet (London, England), 361(9360), 799-808.
